|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS
|
|
|
|
|
|
|
GU Cancer Highlights at the 2024 AUA Annual Meeting
|
|
David Penson, MD, MPH, MMHC
|
| Sam Chang hosts David Penson to shed light on the AUA 2024 meeting in San Antonio, focusing on the fresh, innovative sessions designed to elevate clinical practice. Dr. Penson introduces the P2 program—Practice-changing, Paradigm-shifting Research—aimed at spotlighting pivotal new clinical trials. With an impressive submission of about 90 studies, the program is set to feature eight groundbreaking cancer studies, promising significant impacts on urological practice.
|
|
|
|
|
|
|
|
|
|
|
Preparing for New Insights: AUA 2024 Annual Meeting Data Refresher
|
|
|
|
| TAR-200 in Combination with Cetrelimab for BCG Unresponsive Bladder Cancer (SunRISe-1) |
Siamak Daneshmand, MD
In this conversation, Siamak Daneshmand joins Sam Chang in discussing a new treatment option for bladder cancer called TAR-200. The conversation focuses on the late-breaking abstract of the SunRISe-1 trial, which evaluates the efficacy of TAR-200 in BCG unresponsive bladder cancer patients. |
|
|
|
|
|
|
|
|
|
|
| BOND-003 Phase 3 Results: Revolutionizing Bladder Cancer Treatment with Intravesical Cretostimogene Grenadenorepvec Monotherapy for High-Risk BCG-Unresponsive NMIBC |
| Mark Tyson II, MD, MPH |
| Ashish Kamat welcomes Professor Mark Tyson to discuss the BOND-003 study results on CG0070, cretostimogene grenadenorepvec (creto), for BCG-unresponsive non-muscle invasive bladder cancer. Creto, an oncolytic adenovirus, selectively infects and kills cancer cells while sparing normal tissue and induces antitumor immunity. |
|
|
|
|
|
|
|
|
|
|
|
| Extended Node Dissection in Bladder Cancer: SWOG S1011 Trial Insights |
| Seth Lerner, MD, FACS |
| Seth Lerner presents the results of a SWOG-led Phase III surgical trial (SWOG S1011) investigating the anatomic extent of node dissection during radical cystectomy for curable muscle-invasive bladder cancer. The primary goal was to compare disease-free survival (DFS) in patients undergoing cystectomy, contrasting an extended node dissection with standard pelvic lymphadenectomy. |
|
|
|
|
|
|
|
|
|
|
|
| First Results from SunRISe-1 in Patients with BCG Unresponsive High-Risk Non–muscle-Invasive Bladder Cancer Receiving TAR-200 in Combination With Cetrelimab, TAR-200, or Cetrelimab Alone |
| Siamak Daneshmand, MD |
| Siamak Daneshmand presented the first results from the SunRISe-1 trial, focusing on patients with BCG-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) receiving TAR-200 in combination with Cetrelimab, TAR-200 alone, or Cetrelimab alone. Most high-risk NMIBC patients treated with intravesical BCG experience recurrence or progression within 1 to 5 years, leading to a need for alternative treatments. |
|
|
|
|
|
| First Results from BOND-003, a Phase 3 Study of Intravesical Cretostimogene Grenadenorepvec Monotherapy for Patients with High-Risk BCG Unresponsive NMIBC |
| Mark D. Tyson, MD, MPH |
| Mark Tyson presented the initial findings from BOND-003, a phase 3 study evaluating intravesical Cretostimogene grenadenorepvec monotherapy in patients with high-risk BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS). The trial demonstrated a robust complete response rate of 75.7% at any time based on central review, with a durable response seen in a significant proportion of responders. |
|
|
|
|
|
|
|
|
|
|
| State-of-the-art Lecture Landscape of Current Trials with Intravesical Treatment in High Risk BCG naïve NMIBC |
| Ashish Kamat, MD, MBBS |
| Ashish Kamat discussed current trials and intravesical treatment options for high-risk BCG-naïve non-muscle invasive bladder cancer (NMIBC). He highlighted changes in risk stratification and emphasized the significance of classifying all high-grade Ta tumors as high-risk NMIBC. |
|
|
|
|
|
|
|
|
|
|
